Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.

Clinical application study on hematological malignancies treated by autologous peripheral blood hematopoietic stem cell transplantation

[Long Term Curative Effects and Prognostic Analysis of Stem Cell Transplantation for Treating Patients with Peripheral T Cell Lymphoma].

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Autologous Peripheral Blood Stem Cell Transplantation Is More Therapeutically Effective In The Patients With Hematologic And Solid Tumors.

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Clinical Observation and Long-time Follow-up of Patients with Malignant Lymphoma Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

[Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Hematologic Malignancies].

Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]

The effects of autologous hemetopoietic stem cell transplantation( Auto-HSCT) for malignant lymphoma

Effect of autologons peripheral hematopoietic stem cell transplantation on remission and survival rates in patients with lymphoma

Autologous Peripheral Blood Stem Cell Transplantation (Auto-Pbsct) For Treatment Of Malignant Solid Tumor.

Evaluation of Effects of Autologous Peripheral Blood Stem Cell Transplantation on the Response Rates and Survival Rates in the Patients with Refractory or Relapsed Hodgkin Lymphoma and Grey Zone Lymphoma

Clinical Analysis of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients

A Clinical Study of the Hematopoietic Stem Cell Transplantation in 112 Patients with Leukemia and Other Malignant Diseases

[Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation].

[Clinical Outcomes of Peripheral Blood Stem Cell Transplantation for Aggressive Peripheral T-cell Lymphoma].

Autologous peripheral blood stem cell harvest timing by absolute neutrophil count in children and young adult patients: Single-institute experience

HLA-identical Sibling Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Acute Leukemia

Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases

Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation in 15 patients

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia